CT Cardiomegaly vs ASSURE Wearable ECG

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CT Cardiomegaly

by Innolitics

ASSURE Wearable ECG

by Kestra Medical Technologies

AI Verdict

Tool A specializes in automated cardiothoracic ratio measurement from CT images for cardiomegaly detection, providing quantitative data for diagnostic assistance. In contrast, Tool B is a wearable ECG device designed for continuous heart rate monitoring and data collection, integrated into a remote patient platform for ongoing patient management. While both leverage AI in cardiology, their distinct modalities and applications make them suitable for different clinical workflows.

Choose CT Cardiomegaly if…

Choose CT Cardiomegaly if your primary need is automated, quantitative assessment of cardiomegaly directly from CT chest images. This tool is ideal for radiology departments seeking to streamline the measurement of cardiothoracic ratios with AI-powered software, providing objective data in PDF and JSON formats to support diagnostic decisions.

View CT Cardiomegaly →

Choose ASSURE Wearable ECG if…

Choose ASSURE Wearable ECG if you require continuous, long-term heart rate monitoring and data collection for at-risk cardiac patients in an outpatient setting. This wearable device and integrated platform are best suited for clinicians needing to remotely track patient cardiac activity, filter motion artifacts, and receive alert-based notifications for significant events.

View ASSURE Wearable ECG →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CT Cardiomegaly	ASSURE Wearable ECG
Pricing	Contact for pricing	Contact for pricing.
Deployment	Docker Container (Ubuntu 20.04), command-line software	Wearable device, mobile application, and cloud-based remote patient data platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ASSURE Wearable ECG

Tool B offers a wearable device, mobile application, and cloud platform, providing an intuitive experience for both patients and clinicians for continuous monitoring. In contrast, Tool A is a command-line software, which typically requires more technical expertise and is less user-friendly for direct clinical interaction.

Clinical Value

ASSURE Wearable ECG

Tool B provides continuous heart rate monitoring, alert-based notifications, and physiologic trend data for at-risk cardiac patients, enabling proactive management and early intervention. While Tool A offers precise diagnostic assistance for cardiomegaly from CT scans, Tool B's continuous, real-time insights often have a broader and more immediate impact on patient care and outcomes for chronic conditions.

Pricing & Value

Tie

Both Tool A and Tool B require direct contact with the vendor for pricing information. Without transparent pricing or detailed value propositions beyond their features, it is impossible to compare their relative pricing and value effectively.

Enterprise Readiness

Tie

Both tools demonstrate strong enterprise readiness, with FDA clearance, HIPAA compliance, and BAA availability. Tool A's Docker deployment and Tool B's cloud-based platform are both standard and robust solutions for enterprise IT environments in healthcare.

Innovation

ASSURE Wearable ECG

Tool B showcases greater innovation by integrating a novel wearable hardware (SensorFit Garment) with advanced adaptive algorithms (Adaptive Patient Intelligenceu2122) to filter motion artifacts for continuous, real-world monitoring. Tool A, while utilizing AI for automation, applies it to a more traditional diagnostic measurement without the same level of hardware-software integration or real-time adaptive capabilities.

Support & Docs

Tie

The provided structured facts and initial web searches do not offer sufficient specific information regarding the availability, quality, or scope of support and documentation for either Tool A or Tool B. Therefore, a definitive winner cannot be determined in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CT Cardiomegaly	ASSURE Wearable ECG
Name	CT Cardiomegaly	ASSURE Wearable ECG
Company	Innolitics	Kestra Medical Technologies
Primary Function	Automated cardiothoracic ratio measurement from CT chest images for cardiomegaly detection.	Continuous heart rate monitoring and data collection for at-risk cardiac patients.
Input Data Type	CT chest images	ECG data from wearable device

Videos

Demos, reviews, and walkthroughs featuring CT Cardiomegaly and ASSURE Wearable ECG.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for different cardiac patient management scenarios?

Tool A (CT Cardiomegaly) is a command-line software designed to integrate into radiology workflows, likely within PACS or web-based environments, to automatically process CT chest images and generate PDF/JSON reports for cardiomegaly detection. Tool B (ASSURE Wearable ECG) integrates into a remote patient monitoring workflow, where patients wear the device and data is transmitted to the Kestra CareStation cloud-based platform for clinician review and management of at-risk cardiac patients.

What specific measures are in place to ensure the accuracy and reliability of the data provided by each tool, considering their different data sources?

Tool A (CT Cardiomegaly) has been validated against manual measurements by board-certified radiologists, demonstrating a mean difference for cardiothoracic ratio of 0.0012 and for Heart to Chest Area Ratio of 0.0036, both meeting targets. Tool B (ASSURE Wearable ECG) utilizes Quad Channel Processingu2122 and Adaptive Patient Intelligenceu2122 to filter motion artifacts, enhancing the accuracy of continuous heart rate monitoring in real-world settings.

For which specific clinical scenarios or patient populations is each tool most uniquely suited to provide value?

Tool A (CT Cardiomegaly) is best suited for automated, high-throughput screening of CT chest images for cardiomegaly, providing quantitative data to assist in detection. Tool B (ASSURE Wearable ECG) is uniquely suited for continuous heart rate monitoring and data collection for at-risk cardiac patients, particularly those who have completed use of a wearable cardioverter defibrillator, enabling remote tracking of trends and alerts.

What is the typical learning curve for physicians and their staff, and what is the estimated time to realize clinical value from each tool?

For Tool A (CT Cardiomegaly), while it is command-line software, its integration into existing radiology systems could make its use seamless for physicians once set up by IT, providing rapid, automated results. For Tool B (ASSURE Wearable ECG), the learning curve involves patient education for device wear and clinician training on the Kestra CareStation platform, with value realized through continuous monitoring and alert-based notifications for proactive patient management.

What audit-trail capabilities does each tool offer to support clinical documentation and retrospective review?

Tool A (CT Cardiomegaly) outputs PDF and JSON reports containing cardiothoracic ratio values and patient information, which can serve as an audit trail for clinical documentation. Tool B (ASSURE Wearable ECG) offers automatic episode storage and physiologic trend data, with the Kestra CareStation platform providing tools for clinician review of alerts and patient data, likely including audit logs for access and changes.

What are the key considerations for deploying each tool across multiple clinical sites or a larger healthcare system?

For Tool A (CT Cardiomegaly), deployment involves integrating a Docker Container command-line software into the IT infrastructure of each site, requiring standardized CT image input and report handling. For Tool B (ASSURE Wearable ECG), multi-site rollout would involve managing the distribution and patient onboarding for wearable devices, ensuring mobile application connectivity, and providing access and training for the cloud-based Kestra CareStation platform across all clinical sites.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring CT Cardiomegaly or ASSURE Wearable ECG

Backers

Who funded each tool's parent company.

ASSURE Wearable ECG

Longitude Capital